Identification of drugs as single agents or in combination to prevent carcinoma dissemination in a microfluidic 3D environment

Oncotarget

Volumn 6, Issue 34, 2015, Pages 36603-36614

  Bai, Jing ^a,b   Tu, Ting Yuan ^a   Kim, Choong ^c   Thiery, Jean Paul ^a,d,e   Kamm, Roger D ^a,b  

^a SINGAPORE MIT ALLIANCE FOR RESEARCH AND TECHNOLOGY   (Singapore)

^b Massachusetts Institute of Technology Cambridge   (United States)

^c Kyungil University   (South Korea)

^d INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Bladder cancer; Drug screening; Epithelial mesenchymal transition; Microfluidics; Synergistic effect

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; A 8301; ANTINEOPLASTIC AGENT; CANERTINIB; FIBROBLAST GROWTH FACTOR 2; PLATELET DERIVED GROWTH FACTOR; SARACATINIB; SCATTER FACTOR; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; UVOMORULIN;

A549 CELL LINE; ARTICLE; BLADDER CANCER CELL LINE; CANCER INHIBITION; CANCER PREVENTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SCREENING; ENDOTHELIUM CELL; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; METASTASIS POTENTIAL; MICROFLUIDIC ANALYSIS; THREE DIMENSIONAL IMAGING; TISSUE SCAFFOLD; TUMOR MICROENVIRONMENT; UMBILICAL VEIN ENDOTHELIAL CELL; A-549 CELL LINE; CARCINOMA; DEVICES; DRUG EFFECTS; DRUG POTENTIATION; GENETIC TRANSFECTION; LAB ON A CHIP; PATHOLOGY; PROCEDURES; SIGNAL TRANSDUCTION;

A549 CELLS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; EPITHELIAL-MESENCHYMAL TRANSITION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LAB-ON-A-CHIP DEVICES; SIGNAL TRANSDUCTION; TRANSFECTION; TUMOR MICROENVIRONMENT;

EID: 84946866413     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5464     Document Type: Article

References (35)

1. Talmadge JE, Fidler IJ. AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer research. 2010; 70:5649-5669.
2. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nature reviews Cancer. 2002; 2:442-454.
3. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelialmesenchymal transitions in development and disease. Cell. 2009; 139:871-890.
4. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, Lander ES. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009; 138:645-659.
5. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009; 9:265-273.
6. Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nature reviews Molecular cell biology. 2007; 8:221-233.
7. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nature reviews Cancer. 2009; 9:239-252.
8. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646-674.
9. Scheel C, Eaton EN, Li SH, Chaffer CL, Reinhardt F, Kah KJ, Bell G, Guo W, Rubin J, Richardson AL, Weinberg RA. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell. 2011; 145:926-940.
10. Chung S, Sudo R, Vickerman V, Zervantonakis IK, Kamm RD. Microfluidic Platforms for Studies of Angiogenesis, Cell Migration, and Cell-Cell Interactions. Ann Biomed Eng. 2010; 38:1164-1177.
11. Aref AR, Huang RYJ, Yu WM, Chua KN, Sun W, Tu TY, Bai J, Sim WJ, Zervantonakis IK, Thiery JP, Kamm RD. Screening therapeutic EMT blocking agents in a threedimensional microenvironment. Integr Biol-Uk. 2013; 5:381-389.
12. Sharma SV, Haber DA, Settleman J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer. 2010; 10:241-253.
13. Heyder C, Gloria-Maercker E, Hatzmann W, Niggemann B, Zanker KS, Dittmar T. Role of the beta1-integrin subunit in the adhesion, extravasation and migration of T24 human bladder carcinoma cells. Clin Exp Metastasis. 2005; 22:99-106.
14. Chua K, Sim W, Racine V, Lee S, Goh B, Thiery J. A cellbased small molecule screening method for identifying inhibitors of epithelial-mesenchymal transition in carcinoma PLoS One. 2012; 7:e33183.
15. Huang R, Wong M, Tan T, Kuay K, Ng A, Chung V. An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530). Cell Death Dis. 2013; 4:e915.
16. Zhao TT, Le Francois BG, Goss G, Ding K, Bradbury PA, Dimitroulakos J. Lovastatin inhibits EGFR dimerization and AKT activation in squamous cell carcinoma cells: potential regulation by targeting rho proteins. Oncogene. 2010; 29:4682-4692.
17. Tan TZ, Miow QH, Miki Y, Noda T, Mori S, Huang RY, Thiery JP. Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients. EMBO Mol Med. 2014; 11:201404208.
18. Tunica DG, Yin XK, Sidibe A, Stegemann C, Nissum M, Zeng LF, Brunet M, Mayr M. Proteomic analysis of the secretome of human umbilical vein endothelial cells using a combination of free-flow electrophoresis and nanoflow LC-MS/MS. Proteomics. 2009; 9:4991-4996.
19. Wang PF, Nishitani MA, Tanimoto S, Kishimoto T, Fukumori T, Takahashi M, Kanayama HO. Bladder cancer cell invasion is enhanced by cross-talk with fibroblasts through hepatocyte growth factor. Urology. 2007; 69:780-784.
20. Laidler P, Gil D, Pituch-Noworolska A, Ciolczyk D, Ksiazek D, Przybylo M, Litynska A. Expression of beta1-integrins and N-cadherin in bladder cancer and melanoma cell lines. Acta Biochim Pol. 2000; 47:1159-1170.
21. Sigurdsson V, Hilmarsdottir B, Sigmundsdottir H, Fridriksdottir AJ, Ringner M, Villadsen R, Borg A, Agnarsson BA, Petersen OW, Magnusson MK, Gudjonsson T. Endothelial induced EMT in breast epithelial cells with stem cell properties. Plos One. 2011; 6:6.
22. Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H, Kim WJ, Okimoto RA, Bell DW, Sgroi DC, Christensen JG, Settleman J, Haber DA. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103:2316-2321.
23. Gohji K, Nomi M, Niitani Y, Kitazawa S, Fujii A, Katsuoka Y, Nakajima M. Independent prognostic value of serum hepatocyte growth factor in bladder cancer. J Clin Oncol. 2000; 18:2963-2971.
24. De Medina SGD, Popov Z, Chopin DK, Southgate J, Tucker GC, Delouvee A, Thiery JP, Radvanyi F. Relationship between E-cadherin and fibroblast growth factor receptor 2b expression in bladder carcinomas. Oncogene. 1999; 18:5722-5726.
25. Antoine M, Wirz W, Tag CG, Mavituna M, Emans N, Korff T, Stoldt V, Gressner AM, Kiefer P. Expression pattern of fibroblast growth factors (FGFs), their receptors and antagonists in primary endothelial cells and vascular smooth muscle cells. Growth Factors. 2005; 23:87-95.
26. Jokinen J, Dadu E, Nykvist P, Kapyla J, White DJ, Ivaska J, Vehvilainen P, Reunanen H, Larjava H, Hakkinen L, Heino J. Integrin-mediated cell adhesion to type I collagen fibrils. J Biol Chem. 2004; 279:31956-31963.
27. Yamaguchi H, Pixley F, Condeelis J. Invadopodia and podosomes in tumor invasion. Eur J Cell Biol. 2006; 85:213-218.
28. Huveneers S, Danen EH. Adhesion signaling-crosstalk between integrins, Src and Rho. J Cell Sci. 2009; 122:1059-1069.
29. Fujita S, Suzuki H, Kinoshita M, Hirohashi S. Inhibition of cell attachment, invasion and metastasis of human carcinoma cells by anti-integrin beta 1 subunit antibody. Jpn J Cancer Res. 1992; 83:1317-1326.
30. Sabeh F, Shimizu-Hirota R, Weiss SJ. Protease-dependent versus-independent cancer cell invasion programs: threedimensional amoeboid movement revisited. J Cell Biol. 2009; 185:11-19.
31. Cichon M, Radisky D. ROS-induced epithelial-mesenchymal transition in mammary epithelial cells is mediated by NF-κB-dependent activation of Snail. Oncotarget. 2014; 5:2827-2838.
32. Li L, Liu C, Amato R, Chang J, Li W, Li W. CDKL2 promotes epithelial-mesenchymal transition and breast cancer progression. Oncotarget. 2014; 5:10840-10853.
33. Tu TY, Wang Z, Bai J, Sun W, Peng WK, Huang RY, Thiery JP, Kamm RD. Rapid prototyping of concave microwells for the formation of 3D multicellular cancer aggregates for drug screening. Adv Healthc Mater. 2014; 3:609-616.
34. Bai J, Adriani G, Dang TM, Tu TY, Penny HL, Wong SC, Kamm RD, Thiery JP. Contact-dependent carcinoma aggregate dispersion by M2a macrophages via ICAM-1 and β2 integrin interactions. Oncotarget. July 2015; 26231039.
35. Shin Y, Han S, Jeon JS, Yamamoto K, Zervantonakis IK, Sudo R, Kamm RD, Chung S. Microfluidic assay for simultaneous culture of multiple cell types on surfaces or within hydrogels. Nat Protoc. 2012; 7:1247-1259.